Catheter Precision to Attend the Annual European Heart Rhythm Association Conference

Catheter Precision (NYSE American: VTAK) will attend the annual European Heart Rhythm Association (EHRA) conference in Paris from April 12–14, 2026.

Rhea-AI Summary

Catheter Precision (NYSE American: VTAK) will attend the annual European Heart Rhythm Association (EHRA) conference in Paris from April 12–14, 2026. The company said it will use the event to share new data, engage key opinion leaders and educate physicians and distributors about LockeT after CE Mark receipt.

This appearance is the company's first large European conference since LockeT received CE Mark clearance and aims to support expanded product use and commercial momentum.

Argus Apr 8 session

-1.73% close to close Open Argus

Details

News Market Reaction – VTAK

On Apr 8, the day this news came out, VTAK closed 1.73% below the previous close.

Data tracked by StockTitan Argus for the Apr 8 session.

Market Context

This announcement highlights Catheter Precision’s participation at the EHRA conference from April 12...

Analysis

This announcement highlights Catheter Precision’s participation at the EHRA conference from April 12–14, 2026, emphasizing LockeT exposure after receiving the CE Mark and following new clinical data in 139 patients. It continues a series of updates spanning Flyte aviation growth and 2025 financials, which showed revenue of $819 thousand, 92.3% gross margin, and a significant net loss. Investors may monitor how conference engagement translates into LockeT adoption, potential asset monetization, and progress against liquidity and capital‑raising risks disclosed in recent SEC filings.

Key Figures

EHRA conference dates: April 12–14, 2026

EHRA conference dates

April 12–14, 2026

European Heart Rhythm Association conference in Paris

Historical Context

5 past events · Latest: Apr 06

5 events

1. Apr 06

   LockeT clinical data

   24h Move

   +2.1%

   Peer-reviewed LockeT study in 139 patients showing strong procedural outcomes.

2. Apr 02

   Asset sale process

   24h Move

   -1.1%

   Engaged advisor to market electrophysiology business and refocus on Flyte platform.

3. Mar 31

   2025 results & strategy

   24h Move

   -3.8%

   Reported revenue growth but significant net loss while outlining dual-platform strategy.

4. Mar 25

   Aviation expansion

   24h Move

   -4.2%

   Announced expansion of Vision Jet Hops regional platform and fleet growth plans.

5. Mar 16

   Flyte Hops launch

   24h Move

   +4.4%

   Launched Flyte Hops Florida with strong initial bookings and fleet expansion goals.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

european heart rhythm association, ehra, european society of cardiology, ce mark, +1 more

5 terms

european heart rhythm association medical

"it will be attending the annual European Heart Rhythm Association (EHRA) conference"

A professional medical association focused on heart rhythm disorders, their diagnosis, treatment and prevention. It develops clinical guidelines, organizes research and education, and sets training and certification standards that clinicians and device makers often follow; think of it as an industry standards body for heart rhythm care. Investors track its guidance and endorsements because they can shape adoption of therapies, influence regulatory thinking, and affect demand for related drugs, devices or services.

ehra medical

"European Heart Rhythm Association (EHRA) conference in Paris, France from April 12-14, 2026"

The European Heart Rhythm Association (EHRA) is the professional group of doctors and researchers focused on heart rhythm disorders; it issues clinical guidance, training standards, and expert opinions used across hospitals and regulators. Investors watch EHRA statements and certifications because they can act like a trusted referee—boosting confidence and uptake of cardiac drugs, devices or procedures, or prompting extra scrutiny that affects market adoption and regulatory timelines.

european society of cardiology medical

"EHRA is one of several conferences supported by the European Society of Cardiology"

A professional medical organization for heart doctors and researchers that sets widely followed clinical guidelines, publishes research, and organizes major conferences on cardiovascular medicine. Investors watch its guidance and study results like a weather report for the heart-health sector: favorable findings or new recommended practices can boost the outlook for companies selling drugs, devices or diagnostics, while negative or cautionary guidance can dampen demand and valuations.

ce mark regulatory

"first large European conference we are attending since receipt of the CE Mark for LockeT"

A CE mark is a regulatory stamp placed on products to show they meet the European Union’s basic safety, health and environmental rules and can be sold in the European Economic Area. For investors it matters because the mark unlocks market access, affects how quickly a product can generate revenue, and signals regulatory risk and potential compliance costs—think of it as a passport that lets a product enter a large market.

electrophysiology medical

"key opinion leaders in the electrophysiology field"

The study and measurement of the electrical signals that control cells and tissues, most commonly used to diagnose and treat heart rhythm problems and to test how nerves and muscles communicate. Investors care because electrophysiology drives products, procedures and drugs—like monitoring systems, catheter tools and implants—that can alter a medical device or drug maker’s sales, regulatory approvals and clinical trial outcomes; think of it as checking and fixing the wiring that makes the body run.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FORT MILL, S.C., April 08, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK) (“VTAK” or the “Company”) today announced that it will be attending the annual European Heart Rhythm Association (EHRA) conference in Paris, France from April 12-14, 2026.

EHRA is one of several conferences supported by the European Society of Cardiology whose mission is to reduce the number of people with cardiovascular diseases by connecting cardiovascular health professionals around the world to disseminate the latest knowledge, innovations and guidelines. As a community, they work together to empower healthcare providers to transform cardiovascular care from a privilege to a universal right.

David Jenkins, CEO of Catheter Precision, says, “Conferences continue to be a top priority for Catheter Precision. It is at these events that we can share our newest data and meet with key opinion leaders in the electrophysiology field. EHRA 2026 is exciting as this is the first large European conference we are attending since receipt of the CE Mark for LockeT. This is the perfect opportunity to educate new physicians and distributors about LockeT and continue the forward momentum and expanded product use.”

About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.

About VIVO™
Catheter Precision’s VIVO (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE Mark.

About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “expect,” “anticipate,” “potential,” “will,” “may,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, expectations regarding potential strategic transactions, valuation outcomes, market opportunities, and the Company’s growth strategy. These statements involve risks and uncertainties that could cause actual results to differ materially. For a discussion of these risks, please refer to the Company’s filings with the SEC, including its most recent Forms 10-K and 10-Q. The Company undertakes no obligation to update any forward-looking statements.

CONTACTS:

Investor Relations
973-691-2000
IR@catheterprecision.com

# # #

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Catheter Precision (VTAK) attend the EHRA 2026 conference in Paris?

Catheter Precision will attend EHRA in Paris from April 12–14, 2026. According to Catheter Precision, the company plans to present new data and meet electrophysiology key opinion leaders to support physician education and distributor engagement.

What will Catheter Precision (VTAK) showcase about LockeT at EHRA 2026?

Catheter Precision will highlight LockeT data and commercial information to clinicians and distributors. According to Catheter Precision, this is an opportunity to educate new physicians and expand product use following CE Mark clearance.

Why is EHRA 2026 important for Catheter Precision (VTAK)?

EHRA 2026 is important as Catheter Precision will engage European electrophysiology leaders after LockeT CE Mark. According to Catheter Precision, the event supports dissemination of new data and advancing commercial momentum in Europe.

Will Catheter Precision (VTAK) present clinical data at the EHRA conference?

The company indicated it will share its newest data and meet key opinion leaders at EHRA. According to Catheter Precision, presentations and meetings are meant to educate clinicians and discuss LockeT adoption after CE Mark.

How can physicians and distributors learn about LockeT from Catheter Precision (VTAK) at EHRA?

Physicians and distributors can meet company representatives, review new data, and receive product education during EHRA sessions. According to Catheter Precision, staff will focus on demonstrating LockeT capabilities and practical use following CE Mark clearance.

Does Catheter Precision (VTAK) cite any regulatory milestone tied to its EHRA attendance?

Yes, the company cites the CE Mark for LockeT as a milestone informing its EHRA plans. According to Catheter Precision, EHRA is the first large European conference they will attend since receiving LockeT CE Mark.